Literature DB >> 8894367

Patient with both lupus anticoagulant and acute disseminated encephalomyelitis.

Y Matsukawa1, T Mizutani, N Kitamura, M Takei, T Hayama, S Nishinarita, T Horie, S Sawada, A Tagusagawa, M Tsuchiya, T Takasu.   

Abstract

We present the unusual case of 16-year-old girl who developed intractable convulsions five days after the onset of a cold. Meningeal signs, lymphopenia, proteinuria, and lupus anticoagulant were also present. Treatment with anticonvulsants, antituberculous agents, and adenine arabinoside were ineffective. The initiation of methylprednisolone pulse therapy immediately resolved convulsions and fever. The diagnosis, suggested by the clinical course and the marked improvement of the meningoencephalitis by pulse therapy, was an encephalitic form of acute disseminated encephalomyelitis. Clinical and laboratory findings indicated that an immune disorder may have triggered an abnormal response to a viral infection leading to this patient's neurologic disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894367     DOI: 10.1007/bf02229651

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  DIPHENYLHYDANTOIN METABOLISM, BLOOD LEVELS, AND TOXICITY.

Authors:  H KUTT; W WINTERS; R KOKENGE; F MCDOWELL
Journal:  Arch Neurol       Date:  1964-12

2.  Transient lupus anticoagulant and fansidar therapy.

Authors:  R F Jeffrey
Journal:  Postgrad Med J       Date:  1986-09       Impact factor: 2.401

3.  Post-infectious encephalomyelitis: some aetiological mechanisms.

Authors:  P O Behan
Journal:  Postgrad Med J       Date:  1978-11       Impact factor: 2.401

4.  Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis.

Authors:  J Kesselring; D H Miller; S A Robb; B E Kendall; I F Moseley; D Kingsley; E P du Boulay; W I McDonald
Journal:  Brain       Date:  1990-04       Impact factor: 13.501

Review 5.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

6.  Spontaneous infection or vaccination as cause of acute disseminated encephalomyelitis.

Authors:  J Murphy; J Austin
Journal:  Neuroepidemiology       Date:  1985       Impact factor: 3.282

7.  Immunologic and coagulation disorders in chlorpromazine-treated patients.

Authors:  M H Zarrabi; S Zucker; F Miller; R M Derman; G S Romano; J A Hartnett; A O Varma
Journal:  Ann Intern Med       Date:  1979-08       Impact factor: 25.391

8.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

9.  Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome.

Authors:  R A Asherson; M A Khamashta; A Gil; J J Vazquez; O Chan; E Baguley; G R Hughes
Journal:  Am J Med       Date:  1989-04       Impact factor: 4.965

10.  Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis.

Authors:  R T Canoso; R M de Oliveira
Journal:  Am J Hematol       Date:  1988-04       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.